Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent

  • Mostafa M. Hamed, Dalal A. Abou El Ella, Adam B. Keeton, Gary A. Piazza, Matthias Engel, Rolf W. Hartmann, Ashraf H. Abadi
  • MedChemComm, January 2013, Royal Society of Chemistry
  • DOI: 10.1039/c3md00118k

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Professor Ashraf H. Abadi